Optimizing Anti-VEGF Dosing in nAMD and DME: In Search of the Best Regimen
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Activity Description
Pinnacle clinical studies utilizing intravitreal anti-vascular endothelial growth factor (VEGF) therapies for the management of patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) demonstrate significantly enhanced visual and anatomical outcomes, but real-world outcomes are not always comparable. These discrepancies, in part, have been associated with treatment burden and loss of adherence. To address these factors, regimens that reduce the frequency of intravitreal injections have been developed—along with agents and surgically implanted extended-release devices that have the potential to enhance treatment intervals. In this continuing medical education activity, experts in the field compare anti-VEGF dosing and administration regimens used to treat patients with nAMD and DME, and assess new clinical evidence regarding new and emerging anti-VEGF dosing regimens.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with nAMD and DME.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare the anti-VEGF dosing and administration regimens used for the treatment of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Assess new clinical evidence regarding the optimal use of various anti-VEGF dosing regimens used to treat patients with nAMD and DME.
Activity Chair
Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cole Eye Institute
Cleveland Clinic Lerner College of Medicine
Cleveland, OH
Faculty
Sophie J. Bakri, MD
Chair, Department of Ophthalmology
Whitney and Betty MacMillan Professor of Ophthalmology in Honor of Robert R. Waller, MD
Mayo Clinic
Rochester, MN
Judy E. Kim, MD, FARVO, FASRS
Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
Milwaukee, WI
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 31, 2023, to March 30, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Sophie J. Bakri, MD
Consultant: AbbVie, Adverum, Allergan, Apellis, Cholgene, EyePoint, iLumen, Iveric Bio, Kala, Genentech, Novartis, Outlook, Pixium, Regenxbio, Regeneron, Rejuvitas, Re-Vana, Roche, VoxelCloud, Zeiss
Peter K. Kaiser, MD
Consultant: 2020 Onsite, Aerie, AffaMed, Allegro, Allergan, Allgenesis, Alnylam, Alzheon, Annexon, AsclepiX, Aviceda, Bayer, Bausch + Lomb, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim, Chengdu Kanghong, Clearside, DelsiTech, Dompé, DTx Pharma, Duet Therapeutics, EyePoint, Eyevensys, Galecto Biotech, Galimedix, Gemini, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Kera Therapeutics, Kodiak, Kriya, LensGen, Nanoscope, Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra, Omeros, Oxurion, Palatin, Regeneron, Regenxbio, Retinal Sciences, Retrotope, Roivant, Samsung Bioepis, SGN Nanopharma, Stealth BioTherapeutics, Stuart, Sustained Nano Systems, Takeda, Théa, Unity Biotechnology, Zeiss
Judy E. Kim, MD, FARVO, FASRS
Consultant: Alimera, Allergan, Apellis, Astella, Bausch + Lomb, Clearside, DORC, Genentech, Notal Vision, Novartis, Outlook Therapeutics, Regeneron
Independent Research Contractor: Heidelberg, Optos
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com